Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex dealCRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to Share XNobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex dealhttps://pharmaphorum.com/news/nobel-winner-charpentiers-crispr-therapeutics-gets-900m-in-reworked-vertex-deal/
First patient dosed in trial of Allergan/Editas’ CRISPR blindness drugA first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9, Share XFirst patient dosed in trial of Allergan/Editas’ CRISPR blindness drughttps://pharmaphorum.com/news/first-patient-dosed-in-trial-of-allergan-editas-crispr-blindness-drug/
CRISPR gene editing stocks fall after Editas CEO resignsShares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the Share XCRISPR gene editing stocks fall after Editas CEO resignshttps://pharmaphorum.com/news/crispr-gene-editing-stocks-fall-after-editas-ceo-resigns/
